S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

$23.85
+0.09 (+0.38%)
(As of 04/19/2024 ET)
Today's Range
$23.48
$23.87
50-Day Range
$23.76
$32.56
52-Week Range
$22.01
$33.71
Volume
2.41 million shs
Average Volume
1.73 million shs
Market Capitalization
$4.03 billion
P/E Ratio
11.52
Dividend Yield
N/A
Price Target
$35.38

Alkermes MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
48.3% Upside
$35.38 Price Target
Short Interest
Bearish
8.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
0.49mentions of Alkermes in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$292,718 Sold Last Quarter
Proj. Earnings Growth
-7.93%
From $2.27 to $2.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.68 out of 5 stars

Medical Sector

67th out of 909 stocks

Pharmaceutical Preparations Industry

23rd out of 424 stocks

ALKS stock logo

About Alkermes Stock (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Stock Price History

ALKS Stock News Headlines

Alkermes (NASDAQ:ALKS) Stock Rating Reaffirmed by HC Wainwright
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Alkermes (NASDAQ:ALKS) Shares Gap Up After Analyst Upgrade
Breaking Down Alkermes: 5 Analysts Share Their Views
Alkermes exec sells over $290k in company shares
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
ALKS Factor-Based Stock Analysis
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,100
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$35.38
High Stock Price Target
$50.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+48.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
$355.76 million
Pretax Margin
25.34%

Debt

Sales & Book Value

Annual Sales
$1.66 billion
Cash Flow
$2.28 per share
Book Value
$7.21 per share

Miscellaneous

Free Float
161,131,000
Market Cap
$4.03 billion
Optionable
Optionable
Beta
0.55

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives


ALKS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price target for 2024?

10 equities research analysts have issued 12-month price objectives for Alkermes' stock. Their ALKS share price targets range from $25.00 to $50.00. On average, they expect the company's stock price to reach $35.38 in the next year. This suggests a possible upside of 48.3% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2024?

Alkermes' stock was trading at $27.74 at the beginning of 2024. Since then, ALKS stock has decreased by 14.0% and is now trading at $23.85.
View the best growth stocks for 2024 here
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ALKS earnings forecast
.

How can I listen to Alkermes' earnings call?

Alkermes will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) announced its quarterly earnings data on Thursday, February, 15th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by $0.29. The business had revenue of $377.50 million for the quarter, compared to analyst estimates of $362.78 million. Alkermes had a trailing twelve-month return on equity of 16.10% and a net margin of 21.39%. The company's revenue for the quarter was up 23.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.02) EPS.

How will Alkermes' stock buyback program work?

Alkermes announced that its board has initiated a share repurchase plan on Thursday, February 15th 2024, which permits the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 8.2% of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its stock is undervalued.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus earnings per share estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.09%), Allspring Global Investments Holdings LLC (0.07%), State of Alaska Department of Revenue (0.06%), Maryland State Retirement & Pension System (0.04%), Diversified Trust Co (0.02%) and Guidance Capital Inc. (0.01%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
This page (NASDAQ:ALKS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners